News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,359 Results
Type
Article (38943)
Company Profile (276)
Press Release (643140)
Section
Business (203802)
Career Advice (1983)
Deals (35354)
Drug Delivery (83)
Drug Development (80765)
Employer Resources (168)
FDA (16085)
Job Trends (14793)
News (344437)
Policy (32429)
Tag
Academia (2530)
Alliances (49029)
Alzheimer's disease (1191)
Approvals (16004)
Artificial intelligence (110)
Bankruptcy (352)
Best Places to Work (11437)
Biotechnology (196)
Breast cancer (95)
Cancer (840)
Career advice (1654)
Cell therapy (189)
Clinical research (63798)
Collaboration (300)
Compensation (155)
COVID-19 (2517)
Cystic fibrosis (78)
Data (774)
Diabetes (122)
Diagnostics (6073)
Drug pricing (74)
Earnings (83913)
Employer resources (145)
Events (108607)
Executive appointments (227)
FDA (16488)
Funding (263)
Gene therapy (143)
GLP-1 (548)
Government (4314)
Healthcare (18646)
Infectious disease (2585)
Inflammatory bowel disease (99)
Interviews (306)
IPO (16250)
Job creations (3623)
Job search strategy (1414)
Layoffs (405)
Legal (7847)
Lung cancer (148)
Manufacturing (139)
Medical device (13122)
Medtech (13127)
Mergers & acquisitions (19090)
Metabolic disorders (336)
Neuroscience (1419)
NextGen Class of 2024 (6492)
Non-profit (4461)
Northern California (1108)
Obesity (202)
Opinion (175)
Patents (92)
People (56070)
Phase I (19783)
Phase II (28088)
Phase III (20983)
Pipeline (190)
Postmarket research (2553)
Preclinical (8417)
Radiopharmaceuticals (234)
Rare diseases (176)
Real estate (5887)
Regulatory (21411)
Research institute (2306)
Resumes & cover letters (347)
Southern California (1025)
Startups (3560)
United States (10924)
Vaccines (524)
Weight loss (151)
Date
Today (135)
Last 7 days (662)
Last 30 days (2617)
Last 365 days (36088)
2024 (29459)
2023 (40074)
2022 (51174)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35021)
2017 (32112)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (185)
Asia (36963)
Australia (6026)
California (2531)
Canada (1131)
China (193)
Colorado (109)
Connecticut (107)
Europe (79117)
Florida (362)
Georgia (88)
Illinois (296)
Indiana (172)
Kansas (95)
Maryland (484)
Massachusetts (2052)
Michigan (141)
Minnesota (242)
New Jersey (775)
New York (769)
North Carolina (648)
Northern California (1108)
Ohio (120)
Pennsylvania (721)
South America (1091)
Southern California (1025)
Texas (348)
Utah (73)
Washington State (294)
682,359 Results for "therapeuticsmd inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the first quarter ended March 31, 2024.
May 10, 2024
·
5 min read
Business
TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.
March 29, 2024
·
5 min read
Business
TherapeuticsMD Announces Third Quarter 2023 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the third quarter ended September 30, 2023.
November 14, 2023
·
6 min read
Business
TherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the second quarter ended June 30, 2023.
August 14, 2023
·
4 min read
Business
TherapeuticsMD Announces First Quarter 2023 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the first quarter ended March 31, 2023.
May 15, 2023
·
4 min read
Business
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD, Inc. today reported financial results for the full year ended December 31, 2022.
April 7, 2023
·
6 min read
Business
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited.
January 3, 2023
·
5 min read
Business
TherapeuticsMD Announces Third Quarter 2022 Financial Results
TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the third quarter ended September 30, 2022.
November 14, 2022
·
12 min read
Deals
TherapeuticsMD Announces Additional $7 Million Private Placement
TherapeuticsMD, Inc. announced today that it received an additional $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP.
October 31, 2022
·
4 min read
BioMidwest
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
TherapeuticsMD, Inc. announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited, an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States.
December 4, 2022
·
9 min read
1 of 68,236
Next
